Physician profile
Emad Daher
NPI 1265415285
$10,354.58
in general payments reported to CMS, 2019-2025
49 companies · $1,943 in 2025
The $1,943 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $904 · 2021: $1,316 · 2022: $1,575 · 2023: $1,507 · 2024: $1,900 · 2025: $1,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,350.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,349.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,279.65 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $1,274.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $999.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $756.78 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $597.08 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Otsuka America Pharmaceutical, INC. | $440.39 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $411.03 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $308.50 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $265.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.60 | 2019-2024 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $239.93 | 2019-2021 | |
| Glaxosmithkline, LLC. | $191.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $164.27 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $158.22 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Daher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.